Korean Biotech Firms Struggle as Drug Trials Fail, Triggering Liquidations and Layoffs
According to the pharmaceutical and biotechnology industry on the 17th, drug research and development company OsteoNeuroGen is set to hold an extraordinary shareholders’ meeting on the 25th to propose the company’s dissolution. (Image from OsteoNeuroGen webpage) SEOUL, June 18 (Korea Bizwire) — A string of clinical trial failures is putting severe financial strain on South…










